Here are the 10-K annual reports from CG Oncology, Inc. (CGON) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CGON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGON filings page.
CG Oncology, Inc. is a late-stage biopharmaceutical company focused on cretostimogene grenadenorepvec, an oncolytic immunotherapy for bladder cancer. The drug is designed to selectively kill tumor cells and trigger an immune response through intravesical delivery, similar to BCG.
The lead program targets high-risk BCG-unresponsive non-muscle invasive bladder cancer, where Phase 3 BOND-003 Cohort C showed a 75.5% complete response rate at any time and durable responses out to 24 months, supporting a Biologics License Application initiated in late 2025. Additional Phase 3 and Phase 2 trials extend into intermediate-risk, BCG-naïve and BCG-exposed disease, and muscle-invasive settings.
The company is building a U.S. commercial organization, relies on third-party manufacturing including majority-owned Biovire, and holds regional partnerships with Kissei and Lepu. Intellectual property consists of multiple issued patents and applications covering cretostimogene use and combinations, with expected expiries into the late 2030s and 2040s.